TY - JOUR
T1 - High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia
AU - Vannata, Barbara
AU - Innocenti, Idanna
AU - Autore, Francesco
AU - Sora', Federica
AU - Chiusolo, Patrizia
AU - Leone, Giuseppe
AU - Sica, Simona
AU - Laurenti, Luca
PY - 2012
Y1 - 2012
N2 - Ofatumumab (Ofa) is a new monoclonal anti-CD20 antibody\r\nwith a high efficacy in fludarabine- and alemtuzumab-refractory B cell\r\nchronic lymphocytic leukemia (B-CLL) [1,2]. Data showing an advantage\r\nwith the addiction of high dose corticosteroids to the Ofa at standard dose in\r\nthis type of patients, obtaining an OR rate of 78%, have recently been published\r\nin the literature [3].
AB - Ofatumumab (Ofa) is a new monoclonal anti-CD20 antibody\r\nwith a high efficacy in fludarabine- and alemtuzumab-refractory B cell\r\nchronic lymphocytic leukemia (B-CLL) [1,2]. Data showing an advantage\r\nwith the addiction of high dose corticosteroids to the Ofa at standard dose in\r\nthis type of patients, obtaining an OR rate of 78%, have recently been published\r\nin the literature [3].
KW - Chronic Lymphocytic Leukemia
KW - Chronic Lymphocytic Leukemia
UR - https://publicatt.unicatt.it/handle/10807/40290
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84869214436&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84869214436&origin=inward
U2 - 10.1002/ajh.23349
DO - 10.1002/ajh.23349
M3 - Article
SN - 1096-8652
VL - 87
SP - N/A-N/A
JO - American Journal of Hematology
JF - American Journal of Hematology
IS - 12
ER -